5453-98-5

Basic information

• Product Name: 2,3-DIHYDRO-1H-INDEN-5-YLACETIC ACID
• Synonyms: 2-(2,3-dihydro-1H-inden-5-yl)acetic acid;2,3-Dihydro-1H-Inden-5-Ylacetic Acid(WX610256)
• CAS NO: 5453-98-5
• Molecular Formula: C₁₁H₁₂O₂
• Molecular Weight: 176.22
• Mol File: 5453-98-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 113-114 °C
• Boiling Point: 333°Cat760mmHg
• Flash Point: 230.1°C
• Appearance: /
• Density: 1.207g/cm³
• Vapor Pressure: 5.56E-05mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: 2-8°C
• PKA: 4.40±0.10(Predicted)
• CAS DataBase Reference: 2,3-DIHYDRO-1H-INDEN-5-YLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-DIHYDRO-1H-INDEN-5-YLACETIC ACID(5453-98-5)
• EPA Substance Registry System: 2,3-DIHYDRO-1H-INDEN-5-YLACETIC ACID(5453-98-5)

Safety Data

• Hazardous Substances Data: 5453-98-5(Hazardous Substances Data)

Usage

General Description

2,3-Dihydro-1H-inden-5-ylacetic acid is a chemical compound with the molecular formula C12H12O2. It is a derivative of indene and has a carboxylic acid functional group. 2,3-DIHYDRO-1H-INDEN-5-YLACETIC ACID is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and active pharmaceutical ingredients. It is also known for its anti-inflammatory and analgesic properties, making it a potential candidate for the development of new therapeutic agents. 2,3-Dihydro-1H-inden-5-ylacetic acid has a unique molecular structure that makes it a valuable tool for drug discovery and development.

InChI:InChI=1/C11H12O2/c12-11(13)7-8-4-5-9-2-1-3-10(9)6-8/h4-6H,1-3,7H2,(H,12,13)

Upstream product

• 158094-20-3 2-Indan-5-yl-1-morpholin-4-yl-ethanethione 
• 24425-40-9 indan-5-amine 
• 132464-83-6 2,3-dihydro-5-iodo-1H-indene 
• 858225-07-7 indan-5-yl-acetic acid ethyl ester 

Relevant articles and documents

Discovery of indane propanamides as potent and selective TRPV1 antagonists

A series of indane-type acetamide and propanamide analogues were investigated as TRPV1 antagonists. The analysis of structure–activity relationship indicated that indane A-region analogues exhibited better antagonism than did the corresponding 2,3-dihydrobenzofuran and 1,3-benzodioxole surrogates. Among them, antagonist 36 exhibited potent and selective antagonism toward capsaicin for hTRPV1 and mTRPV1. Further, in vivo studies indicated that antagonist 36 showed excellent analgesic activity in both phases of the formalin mouse pain model and inhibited the pain behavior completely at a dose of 1 mg/kg in the 2nd phase.

Selective κ-opioid agonists: Synthesis and structure-activity relationships of piperidines incorporating an oxo-containing acyl group

This study describes the synthesis and the structure-activity relationships (SARs) of the (S)-(-)-enantiomers of a novel class of 2- (aminomethyl)piperidine derivatives, using κ-opioid binding affinity and antinociceptive potency as the indices of biological activity. Compounds incorporating the 1-tetralon-6-ylacetyl residue (30 and 34-45) demonstrated an in vivo antinociceptive activity greater than predicted on the basis of their κ-binding affinities. In particular, (2S)-2-[(dimethylamino)methyl]- 1-[(5,6,7,8-tetrahydro-5-oxo-2-naphthyl)acetyl]piperidine (34) was found to have a potency similar to spiradoline in animal models of antinociception after subcutaneous administration, with ED50s of 0.47 and 0.73 μmol/kg in the mouse and in the rat abdominal constriction tests, respectively. Further in vivo studies in mice and/or rats revealed that compound 34, compared to other selective κ-agonists, has a reduced propensity to cause a number of κ-related side effects, including locomotor impairment/sedation and diuresis, at antinociceptive doses. For example, it has an ED50 of 26.5 μmol/kg sc in the rat rotarod model, exhibiting a ratio of locomotor impairment/sedation vs analgesia of 36. Possible reasons for this differential activity and its clinical consequence are discussed.